During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|April 19, 2017
Treatment of Follicular Lymphoma: Case 2
Treatment of Follicular Lymphoma
Advertisement
February 2015
- A 44-year-old man presented to his physician with submandibular swelling. He reports losing weight over the past few months.
- Excisional biopsy showed grade 2 follicular lymphoma that was positive for CD20, CD10, Bcl-6 and Bcl-2 co-expression, and t(14;18); KI-67, 15%
- Imaging showed widespread lymphadenopathy and a large mesenteric mass measuring 11.2 cm
- LDH elevated (400 U/L), stage IV follicular lymphoma with bone marrow involvement
- The patient was started on R-CHOP
- PET/CT imaging at end of therapy was consistent with a complete remission.
November 2015
- Follow-up PET/CT at 9 months showed increasing size of the mesenteric mass and progression in the axillary lymph nodes.
- A biopsy was pursued at that time confirming relapsed follicular lymphoma.
- The patient was initiated on obinutuzumab + bendamustine with plan for obinutuzumab maintenance.
October 2016
- Eleven months later, the patient reported having fever and fatigue along with increased swelling in the submandibular node.
- PET/CT showed widespread progression with increased size of the mesenteric mass to 12.5 cm and 3 new lesions (3.2 cm, 2.4 cm, 1.8 cm) in the inguinal region.
- The patient was started on therapy with idelalisib.
- He experienced severe diarrhea from this treatment which was successfully managed with enteric budesonide and systemic corticosteroids.
Advertisement
Related to this article
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
Novocure’s Optune Mya Gets FDA Not Approvable Letter
5